Similar articles for PMID: 15110784

Year	Number of Results
1977	1
1994	1
1995	1
1996	1
1997	1
1999	1
2002	1
2004	7
2005	9
2006	8
2007	11
2008	4
2009	8
2010	6
2011	7
2012	3
2013	4
2014	5
2015	3
2018	3
2019	1
2020	2
2024	0

1

Anti-HCV activities of selective polyunsaturated fatty acids.

Leu GZ, Lin TY, Hsu JT. Leu GZ, et al. Biochem Biophys Res Commun. 2004 May 21;318(1):275-80. doi: 10.1016/j.bbrc.2004.04.019. Biochem Biophys Res Commun. 2004. PMID: 15110784

2

Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy.

Okuse C, Rinaudo JA, Farrar K, Wells F, Korba BE. Okuse C, et al. Antiviral Res. 2005 Jan;65(1):23-34. doi: 10.1016/j.antiviral.2004.09.002. Antiviral Res. 2005. PMID: 15652968

3

Antiviral action of interferon-alpha against hepatitis C virus replicon and its modulation by interferon-gamma and interleukin-8.

Jia Y, Wei L, Jiang D, Wang J, Cong X, Fei R. Jia Y, et al. J Gastroenterol Hepatol. 2007 Aug;22(8):1278-85. doi: 10.1111/j.1440-1746.2007.04957.x. Epub 2007 Jun 12. J Gastroenterol Hepatol. 2007. PMID: 17565587

4

Oncostatin M synergistically inhibits HCV RNA replication in combination with interferon-alpha.

Ikeda M, Mori K, Ariumi Y, Dansako H, Kato N. Ikeda M, et al. FEBS Lett. 2009 May 6;583(9):1434-8. doi: 10.1016/j.febslet.2009.03.054. Epub 2009 Mar 28. FEBS Lett. 2009. PMID: 19332062 Free article.

5

[The direct antiviral effect of interferon-gamma on hepatitis C virus replicon].

Jia YT, Wei L, Jiang D, Cong X, Fei R. Jia YT, et al. Zhonghua Gan Zang Bing Za Zhi. 2006 Jan;14(1):7-10. Zhonghua Gan Zang Bing Za Zhi. 2006. PMID: 16420756 Chinese.

6

Inhibition of intracellular hepatitis C virus replication by nelfinavir and synergistic effect with interferon-alpha.

Toma S, Yamashiro T, Arakaki S, Shiroma J, Maeshiro T, Hibiya K, Sakamoto N, Kinjo F, Tateyama M, Fujita J. Toma S, et al. J Viral Hepat. 2009 Jul;16(7):506-12. doi: 10.1111/j.1365-2893.2009.01102.x. Epub 2009 Mar 3. J Viral Hepat. 2009. PMID: 19302339

7

Ribavirin up-regulates the activity of double-stranded RNA-activated protein kinase and enhances the action of interferon-alpha against hepatitis C virus.

Liu WL, Su WC, Cheng CW, Hwang LH, Wang CC, Chen HL, Chen DS, Lai MY. Liu WL, et al. J Infect Dis. 2007 Aug 1;196(3):425-34. doi: 10.1086/518894. Epub 2007 Jun 25. J Infect Dis. 2007. PMID: 17597457

8

Different anti-HCV profiles of statins and their potential for combination therapy with interferon.

Ikeda M, Abe K, Yamada M, Dansako H, Naka K, Kato N. Ikeda M, et al. Hepatology. 2006 Jul;44(1):117-25. doi: 10.1002/hep.21232. Hepatology. 2006. PMID: 16799963

9

The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro.

Paeshuyse J, Kaul A, De Clercq E, Rosenwirth B, Dumont JM, Scalfaro P, Bartenschlager R, Neyts J. Paeshuyse J, et al. Hepatology. 2006 Apr;43(4):761-70. doi: 10.1002/hep.21102. Hepatology. 2006. PMID: 16557546 Free article.

10

Inhibition of hepatitis C virus replication by arsenic trioxide.

Hwang DR, Tsai YC, Lee JC, Huang KK, Lin RK, Ho CH, Chiou JM, Lin YT, Hsu JT, Yeh CT. Hwang DR, et al. Antimicrob Agents Chemother. 2004 Aug;48(8):2876-82. doi: 10.1128/AAC.48.8.2876-2882.2004. Antimicrob Agents Chemother. 2004. PMID: 15273095 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

81 results

Results by year